Welcome to Health Care POV | sign in | join
The Power of Two

Can You Say Loophole?

Published April 8, 2014 12:10 PM by Eleanor Wolfram

A friend of mine, who happens to be an attorney, loves to curl his lips as he rolls the words, “litigious”  and “loophole” off his tongue. He is so cheerful when he enunciate these terms; you would think that he is preparing for a singing role in a opera. His favorite phase is, “We live in a litigious and loophole society”.

Well, he is partly right on this matter. These days you can file a lawsuit against a lightning bug (Lampyridae aka firefly), if the bug’s flashes her light too often for your liking. The problem is lawsuits often get tangled up for years before being resolved or settled. This brings me to the theme of this post – confusing healthcare loopholes.

FDA and NIH Mind Merge
Just recently, I was reading that the future of commercializing a promising stem cell research finding for blindness and age-related muscular degenerative may be held up due to loopholes and legal red tape involving two governmental agencies. The hold up has to do with proactive versus reactive (after the fact) testing of potential embryo disease HIV, hepatitis and infectious microorganisms that may be laying dormant.

It seems that the National Institutes of Health’s (NIH) research rules and guidelines do not match up with the Food and Drug Administration’s (FDA) regulations for embryonic stem cell research and therapies. 

Why is this important? It’s important because the consequence may mean that the research findings can end up not moving beyond the researcher’s lab bench onto the market place which is the ultimate goal.

I’ll keep you posted if a resolution between NIH and FDA occurs in the near future.

posted by Eleanor Wolfram


leave a comment

To prevent comment spam, please type the code you see below into the code field before submitting your comment. If you cannot read the numbers in the image, reload the page to generate a new one.

Enter the security code below: